The Incheon Free Economic Zone Authority (IFEZA) and Incheon Technopark a annoncé le 16th that they operated the 'Smart-X Series Demonstration Bridge Program' l'année dernière, providing demonstration resources notamment space, infrastructure/plateformes, data, and experts to 21 startups, thereby supporting early commercialization of their products and services.
The program leverages the technologies held by startups and the demonstration resources of public-private cooperation partners tels que Incheon Port Authority, Incheon Urban Corporation, Celltrion, and Hanlim Pharmaceutical to commercialize startup products and services.
The three companies selected for the Hanlim Pharmaceutical program — RudaCure, Renatus, and Mbiome Therapeutics — achieved results notamment 12 new hires, KRW 750 million in revenue (provisional), and 3 overseas patents.
RudaCure established a pipeline for developing an ocular implant plateforme for wet age-related macular degeneration treatment RCI005 and supported follow-up research; Renatus laid the groundwork for developing RN-005 for degenerative retinal disease treatment; and Mbiome Therapeutics established a large-scale production process and mass-produced LAB-pc001, the raw material for a microbiome-based Crohn's disease treatment.
Jang Byung-hyeon, Head of Planning and Coordination at IFEZA, a déclaré : "This year we will work to secure additional cooperation partners for the Demonstration Bridge Program, advance the entire city as a free demonstration zone, and provide substantial support to help startups commercialize their products and services."